Literature DB >> 17404776

Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations.

M Deschauer1, A Morgenroth, P R Joshi, D Gläser, P F Chinnery, J Aasly, H Schreiber, M Knape, S Zierz, M Vorgerd.   

Abstract

BACKGROUND: McArdle disease, a common metabolic myopathy with autosomal recessive inheritance, is caused by a frequent R50X mutation and many rare mutations in the myophosphorylase gene.
OBJECTIVES: To identify spectrum and frequencies of myophosphorylase gene mutations in a large cohort of patients with McArdle disease, to discuss diagnostic implications, and to analyse genotype-phenotype relationship.
METHODS: Molecular genetic analysis of 56 index patients with muscle biopsy-proven myophosphorylase deficiency from Germany (n = 35), UK (n = 13), and several other countries (n = 8) was performed using direct sequencing.
RESULTS: Allele frequency of the R50X mutation was 58%, and 71% of the patients carried this mutation at least on one allele. We detected 26 other less common mutations, 13 of which are novel: G157V, R161C, Q337R, E384K, S450L, G486D, R570W, K575E, IVS6-2A>T, IVS10+1G>A, R650X, c.1354insC, c.1155_1156delGG. There was no genotype-phenotype correlation with respect to age of onset and severity. R270X was the most frequent mutation among the less common mutations reaching an allele frequency of 5% followed by R94W and G686R representing a frequency of 4% each.
CONCLUSIONS: The study further extends the genetic heterogeneity of myophosphorylase gene mutations showing no mutational hotspot and no genotype-phenotype correlation. Most novel missense mutations were located in secondary structures or active sites of the enzyme. Some of the less common mutations are recurrent with different frequencies within Europe. Ethnic origin and frequency of less common mutations must be considered to establish efficient strategies in molecular genetic testing. Performing molecular testing can avoid muscle biopsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404776     DOI: 10.1007/s00415-006-0447-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  A novel nonsense mutation (R269X) in the myophosphorylase gene in a patient with McArdle disease.

Authors:  M Deschauer; J R Opalka; A Lindner; S Zierz
Journal:  Mol Genet Metab       Date:  2001-12       Impact factor: 4.797

2.  McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases.

Authors:  C Bartram; R H Edwards; J Clague; R J Beynon
Journal:  Hum Mol Genet       Date:  1993-08       Impact factor: 6.150

3.  Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease).

Authors:  S Tsujino; S Shanske; S DiMauro
Journal:  N Engl J Med       Date:  1993-07-22       Impact factor: 91.245

4.  A novel mutation in the PYGM gene in a family with pseudo-dominant transmission of McArdle disease.

Authors:  Paul J Isackson; Mark Tarnopolsky; Georgirene D Vladutiu
Journal:  Mol Genet Metab       Date:  2005-04-07       Impact factor: 4.797

Review 5.  Myophosphorylase deficiency (glycogenosis type V; McArdle disease).

Authors:  S Dimaur; A L Andreu; C Bruno; G M Hadjigeorgiou
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

6.  Evolution of allosteric control in glycogen phosphorylase.

Authors:  J W Hudson; G B Golding; M M Crerar
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

Review 7.  McArdle's disease presenting with asymmetric, late-onset arm weakness.

Authors:  G I Wolfe; N S Baker; R G Haller; D K Burns; R J Barohn
Journal:  Muscle Nerve       Date:  2000-04       Impact factor: 3.217

8.  Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle's disease.

Authors:  M A Martín; J C Rubio; R A Wevers; B G M Van Engelen; G C H Steenbergen; O P Van Diggelen; M De Visser; C De Die-Smulders; A Blázquez; A L Andreu; J Arenas
Journal:  Ann Hum Genet       Date:  2004-01       Impact factor: 1.670

9.  Two novel mutations in the myophosphorylase gene in a patient with McArdle disease.

Authors:  Marcus Deschauer; Kathrin Hertel; Stephan Zierz
Journal:  Muscle Nerve       Date:  2003-01       Impact factor: 3.217

10.  Molecular characterization of myophosphorylase deficiency in a group of patients from northern Italy.

Authors:  A Martinuzzi; S Tsujino; L Vergani; G Schievano; M Cadaldini; L Bartoloni; M Fanin; G Siciliano; S Shanske; S DiMauro; C Angelini
Journal:  J Neurol Sci       Date:  1996-04       Impact factor: 3.181

View more
  8 in total

1.  Clinical and molecular characterization of McArdle's disease in Brazilian patients.

Authors:  Juliana Gurgel-Giannetti; Gisela Nogales-Gadea; Hélio van der Linden; Túlio Marcus Ribeiro Bellard; Geraldo Brasileiro Filho; Alexandre Varella Giannetti; Eralda Luiza de Castro Concentino; Mariz Vainzof
Journal:  Neuromolecular Med       Date:  2013-05-08       Impact factor: 3.843

2.  The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications.

Authors:  Gisela Nogales-Gadea; Alfredo Santalla; Astrid Brull; Noemi de Luna; Alejandro Lucia; Tomàs Pinós
Journal:  J Inherit Metab Dis       Date:  2014-07-23       Impact factor: 4.982

3.  [Metabolic and mitochondrial myopathies].

Authors:  M Vorgerd; M Deschauer
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

4.  Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease.

Authors:  Güldal Inal-Gültekin; Bahar Toptaş-Hekimoğlu; Zeliha Görmez; Özlem Gelişin; Hacer Durmuş; Bekir Ergüner; Hüseyin Demirci; Mahmut Ş Sağıroğlu; Yeşim Parman; Feza Deymeer; Hülya Yılmaz-Aydoğan; Sadrettin Pençe; Can Ebru Bekircan-Kurt; Ersin Tan; Sevim Erdem-Özdamar; Duran Üstek; Urs Giger; Oğuz Öztürk; Piraye Serdaroğlu-Oflazer
Journal:  Neuromuscul Disord       Date:  2017-06-16       Impact factor: 4.296

5.  Genotypic and phenotypic features of all Spanish patients with McArdle disease: a 2016 update.

Authors:  Alfredo Santalla; Gisela Nogales-Gadea; Alberto Blázquez Encinar; Irene Vieitez; Adrian González-Quintana; Pablo Serrano-Lorenzo; Inés García Consuegra; Sara Asensio; Alfonsina Ballester-Lopez; Guillem Pintos-Morell; Jaume Coll-Cantí; Helios Pareja-Galeano; Jorge Díez-Bermejo; Margarita Pérez; Antoni L Andreu; Tomàs Pinós; Joaquín Arenas; Miguel A Martín; Alejandro Lucia
Journal:  BMC Genomics       Date:  2017-11-14       Impact factor: 3.969

6.  Absence of p.R50X Pygm read-through in McArdle disease cellular models.

Authors:  Guillermo Tarrasó; Alberto Real-Martinez; Marta Parés; Lídia Romero-Cortadellas; Laura Puigros; Laura Moya; Noemí de Luna; Astrid Brull; Miguel Angel Martín; Joaquin Arenas; Alejandro Lucia; Antoni L Andreu; Jordi Barquinero; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Dis Model Mech       Date:  2020-01-13       Impact factor: 5.758

Review 7.  Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach.

Authors:  Pushpa Raj Joshi; Stephan Zierz
Journal:  Molecules       Date:  2020-04-13       Impact factor: 4.411

Review 8.  Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies.

Authors:  Mónica Villarreal-Salazar; Astrid Brull; Gisela Nogales-Gadea; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alfredo Santalla; Alejandro Lucia; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.